Search Tag: dapagliflozin

Cardiology Management

Esccongress-results-from-vanish-and-dapa-hf

2021 27 Aug

At the ESC Congress 2021 today, latest insights into the progression to, and management of, heart failure were presented.   Dr Carolyn Ho of Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA,  discussed the results of the VANISH (Valsartan for Attenuating Disease Evolution in Early Sarcomeric HCM) trial. This trial...Read more

Cardiology Management

Esccongress-findings-from-dapa-ckd-trial

2020 30 Aug

The main results of the DAPA-CK trial were presented today at ESC Congress 2020. Findings showed that dapagliflozin reduces the risk of kidney failure, death from cardiovascular causes or heart failure hospitalisation and all-cause mortality in chronic kidney disease patients with or without type 2 diabetes. The goal of the DAPA-CKD trial was to...Read more

Cardiology Management

Esccongress-dapa-hf-trial-reduction-in-cardiovascular-death-hospitalisation

2019 01 Sep

The DAPA-HF study findings were presented today by Dr. John McMurray at the ESC Congress in Paris.  DAPA-HF is an international, multi-centre, parallel-group, randomised, double-blind trial in patients with heart failure and reduced ejection fraction (LVEF = 40%), with and without type-2 diabetes, designed to evaluate the effect of dapagliflozin,...Read more

Cardiology Management

Esccongress-preview-dapa-hf-trial

2019 29 Aug

The DAPA-HF trial is the first heart failure outcomes trial with dapagliflozin, an SGLT2 inhibitor, in patients with and without Type-2 diabetes. Findings from the trial will be presented at the ESC Congress next week.  DAPA-HF is an international, multi-centre, parallel-group, randomised, double-blind trial in patients with heart failure...Read more